Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.37 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.60 | 3.92 | 6.85 | 6.17 | 16.38 | 32.99 | 10.91 | 7.23 | 8.17 | 32.26 | 151.52 | 156.27 | 791.54 | — | — | — | — | — | — | — | — |
| — | -88.1% | -37.2% | -14.7% | +100.4% | +2.3% | -92.8% | -95.4% | -99.0% | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.19 | 0.95 | 0.83 | 0.54 | 0.93 | 1.57 | 0.59 | 0.53 | 1.24 | 6.77 | 13.91 | 22.38 | 104.52 | 207.35 | 229.32 | 115.48 | 99.80 | 136.26 | 5779.00 | 7379.24 | 1.09 |
| — | -39.1% | +41.2% | +1.4% | -25.0% | -76.8% | -95.8% | -97.6% | -98.8% | -96.7% | -93.9% | -80.6% | +4.7% | +52.2% | -96.0% | -98.4% | +9062.9% | -99.3% | -72.5% | -41.5% | -100.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 34.7% | 94.8% | 69.0% | 71.3% | 58.4% | -63.8% | 61.2% | 54.2% | 44.9% | -52.5% | 33.1% | -2.1% | 40.5% | — | — | — | — | — | — | — | — |
| — | +248.7% | +12.8% | +31.6% | +30.2% | -21.5% | +84.7% | +2691.9% | +10.9% | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -959.1% | -314.1% | -603.9% | -895.8% | -1005.1% | -1416.2% | -660.9% | -870.6% | -551.2% | -831.5% | -860.2% | -723.2% | -705.6% | — | — | — | — | — | — | — | — |
| — | +77.8% | +8.6% | -2.9% | -82.4% | -70.3% | +23.2% | -20.4% | +21.9% | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -946.2% | -299.4% | -584.4% | -870.3% | -972.9% | -1415.0% | -692.8% | -856.2% | -503.6% | -3567.8% | -601.9% | -723.0% | -701.3% | — | — | — | — | — | — | — | — |
| — | +78.8% | +15.7% | -1.6% | -93.2% | +60.3% | -15.1% | -18.4% | +28.2% | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -64.5% | -18.0% | -17.0% | -19.7% | -16.0% | -16.2% | -10.5% | -20.7% | -24.4% | -104.9% | -14.0% | -24.1% | -21.4% | -18.5% | -17.7% | -14.5% | -11.9% | -9.9% | -12.4% | -14.0% | -9.7% |
| — | -11.2% | -61.8% | +4.8% | +34.4% | +84.5% | +24.8% | +14.3% | -14.1% | -465.6% | +21.1% | -66.2% | -80.5% | -87.4% | -43.1% | -3.5% | -22.5% | +24.9% | +20.7% | +38.0% | +53.1% | |
| ROA | -56.4% | -15.8% | -15.0% | -17.7% | -14.6% | -14.9% | -9.5% | -17.1% | -17.2% | -76.6% | -10.3% | -18.6% | -18.7% | -16.7% | -16.3% | -13.5% | -11.2% | -9.3% | -11.4% | -13.0% | -9.2% |
| — | -6.5% | -58.8% | -3.3% | +15.4% | +80.6% | +8.2% | +7.8% | +8.1% | -357.7% | +36.8% | -37.5% | -67.5% | -80.8% | -43.4% | -4.3% | -21.8% | +26.8% | +22.4% | +36.8% | +51.8% | |
| ROIC | -222.1% | -70.7% | -76.2% | -90.2% | -58.6% | -45.9% | -25.3% | -33.5% | -22.8% | -17.4% | -15.9% | -20.0% | -18.3% | -20.7% | -27.9% | -27.7% | -21.6% | -19.1% | -36.3% | -72.0% | -76.8% |
| — | -53.9% | -201.6% | -169.4% | -156.5% | -164.2% | -58.8% | -67.7% | -25.1% | +15.8% | +43.0% | +27.8% | +15.6% | -8.4% | +23.0% | +61.6% | +71.8% | +84.1% | +70.2% | +43.5% | +69.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.04 | 0.12 | 0.23 | 0.09 | 0.09 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| — | +95.4% | +82.0% | -85.9% | -98.4% | -98.7% | -96.6% | -59.2% | +1130.7% | +2410.7% | +1363.8% | +2435.2% | +145.9% | +137.9% | +60.8% | -16.1% | -29.7% | -35.1% | -29.1% | -70.8% | -71.4% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.42 | 6.61 | 6.99 | 7.42 | 9.89 | 7.53 | 12.31 | 6.50 | 3.33 | 1.15 | 1.47 | 2.53 | 1.77 | 2.78 | 6.40 | 7.19 | 11.33 | 12.05 | 9.96 | 8.71 | 16.22 |
| — | -12.2% | -43.3% | +14.2% | +197.2% | +556.4% | +737.9% | +157.0% | +88.4% | -58.8% | -77.1% | -64.8% | -84.4% | -76.9% | -35.7% | -17.4% | -30.2% | -45.1% | -65.3% | -2.9% | +14.5% | |
| Quick Ratio | 7.23 | 6.61 | 6.86 | 7.23 | 9.62 | 7.22 | 11.64 | 6.04 | 2.81 | 0.72 | 0.87 | 1.78 | 1.02 | 2.04 | 6.40 | 7.19 | 11.33 | 12.05 | 9.96 | 8.71 | 16.22 |
| — | -8.4% | -41.0% | +19.6% | +242.8% | +904.9% | +1243.7% | +239.3% | +176.2% | -64.8% | -86.5% | -75.2% | -91.0% | -83.1% | -35.7% | -17.4% | -30.2% | -45.1% | -65.3% | -2.9% | +14.5% | |
| Interest Coverage | -1392.49 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TNXP stock.
Tonix Pharmaceuticals Holding Corp.'s current P/E is -0.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Tonix Pharmaceuticals Holding Corp.'s current operating margin is -959.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Tonix Pharmaceuticals Holding Corp.'s business trajectory between earnings reports.